ATE527271T1 - Prodrugs von combretastatin a-1 phosphat und combretastatin b-1 phosphat - Google Patents
Prodrugs von combretastatin a-1 phosphat und combretastatin b-1 phosphatInfo
- Publication number
- ATE527271T1 ATE527271T1 AT01928978T AT01928978T ATE527271T1 AT E527271 T1 ATE527271 T1 AT E527271T1 AT 01928978 T AT01928978 T AT 01928978T AT 01928978 T AT01928978 T AT 01928978T AT E527271 T1 ATE527271 T1 AT E527271T1
- Authority
- AT
- Austria
- Prior art keywords
- phosphate
- combretastatin
- prodrugs
- combretastin
- prodrug
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
- C07C255/43—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20039500P | 2000-04-27 | 2000-04-27 | |
| PCT/US2001/013858 WO2001081355A1 (en) | 2000-04-27 | 2001-04-27 | Combretastatin a-1 phosphate and combretastatin b-1 phosphate prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE527271T1 true ATE527271T1 (de) | 2011-10-15 |
Family
ID=22741540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01928978T ATE527271T1 (de) | 2000-04-27 | 2001-04-27 | Prodrugs von combretastatin a-1 phosphat und combretastatin b-1 phosphat |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7078552B2 (de) |
| EP (1) | EP1278758B1 (de) |
| AT (1) | ATE527271T1 (de) |
| CA (1) | CA2407675C (de) |
| CY (1) | CY1112310T1 (de) |
| DK (1) | DK1278758T3 (de) |
| ES (1) | ES2395097T3 (de) |
| PT (1) | PT1278758E (de) |
| WO (1) | WO2001081355A1 (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE527271T1 (de) * | 2000-04-27 | 2011-10-15 | Univ Arizona | Prodrugs von combretastatin a-1 phosphat und combretastatin b-1 phosphat |
| EP1438281A4 (de) | 2001-10-26 | 2006-04-26 | Oxigene Inc | Funktionalisierte stilbenderivate als verbesserte, auf das gefässsystem zielende mittel |
| EP1601348A4 (de) | 2003-02-28 | 2008-12-10 | Oxigene Inc | Zusammensetzungen und verfahren mit verbesserter therapeutischer aktivität |
| US20090137687A1 (en) * | 2003-02-28 | 2009-05-28 | Oxigene, Inc. | Compositions and Methods With Enhanced Therapeutic Activity |
| GB0504994D0 (en) | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
| CN1907989B (zh) * | 2005-08-02 | 2011-08-17 | 浙江天皇药业有限公司 | 毛兰素盐及其制备方法和包含其的药物组合物 |
| KR101139413B1 (ko) * | 2006-12-07 | 2012-06-22 | 차이나 메디컬 유니버시티 | 항암제로서 새로운 2-아릴-4-퀴놀론의 친수성 유도체 |
| US20090012325A1 (en) * | 2007-02-22 | 2009-01-08 | Ajith Manage | Methods for preparing phosphoric acids of combrestastatin and derivatives thereof |
| WO2009067706A1 (en) * | 2007-11-21 | 2009-05-28 | Oxigene, Inc. | Method for treating hematopoietic neoplasms |
| WO2010132498A1 (en) * | 2009-05-11 | 2010-11-18 | Oxigene, Inc. | Vascular disrupting agents for treatment of polypoidal choroidal vasculopathy |
| WO2011112988A1 (en) * | 2010-03-11 | 2011-09-15 | Oxigene, Inc. | Ophthalmic formulations |
| EP2576514A1 (de) | 2010-06-04 | 2013-04-10 | Exonhit Sa | Substituierte isochinoline und deren verwendung als tubulinpolymerisationsinhibitoren |
| WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
| EP2972394A4 (de) | 2013-03-15 | 2016-11-02 | Sloan Kettering Inst Cancer | Hsp90-anzielende herzbildgebung und -therapie |
| WO2016130969A1 (en) | 2015-02-13 | 2016-08-18 | George Robert Pettit | Silstatin compounds |
| US11419934B2 (en) | 2015-08-18 | 2022-08-23 | Oncotelic Therapeutics, Inc. | Use of VDAS to enhance immunomodulating therapies against tumors |
| WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
| WO2018144910A1 (en) | 2017-02-02 | 2018-08-09 | Bioventures, Llc | Methods of protecting against neurodegeneration |
| US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| WO2019094709A1 (en) | 2017-11-09 | 2019-05-16 | Pettit George R | Betulastatin compounds |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| WO2022182415A1 (en) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1338645C (en) * | 1987-01-06 | 1996-10-15 | George R. Pettit | Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins" |
| GB9106177D0 (en) * | 1991-03-22 | 1991-05-08 | Aston Molecules Ltd | Substituted diphenylethylenes and analogues or derivatives thereof |
| US5561122A (en) | 1994-12-22 | 1996-10-01 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Combretastatin A-4 prodrug |
| WO1999034788A1 (en) * | 1998-01-09 | 1999-07-15 | Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University | Synthesis of phenstatin and prodrugs thereof |
| EP1045853B1 (de) * | 1998-01-09 | 2010-08-04 | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA acting for and on behalf of ARIZONA STATE UNIVERSITY | Synthese von combretastatin a-4 prodrugs |
| GB9903403D0 (en) * | 1999-02-16 | 1999-04-07 | Angiogene Pharm Ltd | Substituted stilbene compounds with vascular damaging activity |
| WO2000048606A1 (en) * | 1999-02-18 | 2000-08-24 | Oxigene, Inc. | Compositions and methods for use in targeting vascular destruction |
| ATE527271T1 (de) * | 2000-04-27 | 2011-10-15 | Univ Arizona | Prodrugs von combretastatin a-1 phosphat und combretastatin b-1 phosphat |
-
2001
- 2001-04-27 AT AT01928978T patent/ATE527271T1/de active
- 2001-04-27 DK DK01928978.4T patent/DK1278758T3/da active
- 2001-04-27 WO PCT/US2001/013858 patent/WO2001081355A1/en not_active Ceased
- 2001-04-27 CA CA2407675A patent/CA2407675C/en not_active Expired - Lifetime
- 2001-04-27 EP EP01928978A patent/EP1278758B1/de not_active Expired - Lifetime
- 2001-04-27 US US10/258,672 patent/US7078552B2/en not_active Expired - Lifetime
- 2001-04-27 PT PT01928978T patent/PT1278758E/pt unknown
- 2001-04-27 ES ES01928978T patent/ES2395097T3/es not_active Expired - Lifetime
-
2011
- 2011-12-12 CY CY20111101232T patent/CY1112310T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1278758A1 (de) | 2003-01-29 |
| EP1278758A4 (de) | 2005-10-19 |
| CA2407675A1 (en) | 2001-11-01 |
| CA2407675C (en) | 2012-07-10 |
| CY1112310T1 (el) | 2015-12-09 |
| US7078552B2 (en) | 2006-07-18 |
| PT1278758E (pt) | 2011-12-22 |
| WO2001081355A1 (en) | 2001-11-01 |
| ES2395097T3 (es) | 2013-02-08 |
| EP1278758B1 (de) | 2011-10-05 |
| US20030220298A1 (en) | 2003-11-27 |
| DK1278758T3 (da) | 2012-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE527271T1 (de) | Prodrugs von combretastatin a-1 phosphat und combretastatin b-1 phosphat | |
| CY1107927T1 (el) | Ενωσεις φωσφονικου | |
| PT1309589E (pt) | Compostos de ureia e metodos de utilizacao | |
| TR199801151T2 (xx) | Trombin inhibit�r� �n ila�lar. | |
| NO20030748D0 (no) | Prodruger av betulinsyre for behandlingen av kreft og HIV | |
| NO965378D0 (no) | Pyrazolo- og pyrolopyridiner | |
| ATE461698T1 (de) | Gaba-analoga zur verhütung und behandlung gastrointestinaler beschwerden | |
| CY1110113T1 (el) | Φωσφολιπιδιου παραγωγα βαλπροϊκου οξεος και μειγματα αυτων | |
| TR200101722T2 (tr) | Serivastatin ve fibratların birleşimi. | |
| ES2190793T3 (es) | Inhibidores de proteasas retrovirales de heterociclocarbonil aminoacido hidroxietilamino sulfonamida. | |
| ATE271865T1 (de) | Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen | |
| TR199801704T2 (xx) | Serin proteaz inhibit�rleri. | |
| DE602004017871D1 (de) | Zubereitungen zur behandlung von arthritischen erscheinungen | |
| ATE254913T1 (de) | Diacerein zur behandlung von psoriasis | |
| PT994704E (pt) | Utilizacao de analogos do gaba tal como a gabapentina no fabrico de um medicamento para o tratamento de doencas inflamatorias | |
| DE69934096D1 (de) | Zusammensetzungen und methoden zur wundheilung | |
| ES2170143T3 (es) | Composiciones que comprenden halofantrina en una forma especial. | |
| ATE261724T1 (de) | Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen | |
| TWI262791B (en) | 6-methoxy-2-naphthylacetic acid prodrugs | |
| BR9709264A (pt) | Processo para produzir e composto | |
| ATE279918T1 (de) | Verwendung von aloe-emodin zur behandlung von neuroektodermalen tumoren | |
| TR199801492A2 (xx) | S�lfonamid-ikame etmi� bile�ikleri elde etme usulleri. | |
| FI964749A0 (fi) | Asyloituja enolijohdannaisia elastaasi-inhibiittoreiden lääkkeen esiasteina | |
| ES2184093T3 (es) | Procedimiento de estimulacion de cilios. | |
| DK1144348T3 (da) | LTA4-hydrolaseinhibitorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1278758 Country of ref document: EP |